FDA approves Abbott’s Libre Duo 10 Day dual glucose-ketone monitor

Abbott has received FDA authorisation for its Libre Duo 10 Day system, described as the world’s first device to monitor both glucose and ketone levels for people with diabetes. The Libre Duo 10 Day sensor delivers up to ten days of continuous monitoring with ongoing readings, not single-point measurements. The Libre Duo 10 Day aims to address challenges in ketone monitoring by offering background measurement, reducing user burden. Credit: Abbott. Abbott has received authorisation from the US Food and Drug Administration (FDA) for its Libre Duo 10 Day system, described as the world’s first device to monitor both glucose and…

Source: Medical Device Network